Related Experiment Videos
Nomifensine in Parkinson's disease.
British Journal of Clinical Pharmacology
|January 1, 1977
Summary
Nomifensine was studied in Parkinson's disease patients with levodopa resistance or "on-off" fluctuations. The drug did not improve Parkinsonian symptoms but may offer antidepressant benefits for these patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease involves loss of dopaminergic neurons.
- Indirect dopamine agonists may be less effective due to impaired presynaptic mechanisms.
Purpose of the Study:
- To evaluate the antiparkinsonian efficacy of nomifensine in patients with advanced Parkinson's disease.
- To assess nomifensine's potential as an adjunctive therapy for levodopa-resistant Parkinson's disease.
Main Methods:
- Eight patients with levodopa failure or
- on-off
- phenomenon received additional nomifensine (50-150 mg daily) for 2-5 months.
- Assessments were performed bi-weekly using a validated rating scale.
- Other antiparkinsonian medications remained unchanged.
Main Results:
- Nomifensine did not demonstrate antiparkinsonian value in this patient cohort.
- No significant improvement in motor symptoms was observed.
Conclusions:
- Nomifensine is not effective for treating Parkinson's disease motor symptoms in patients with advanced disease.
- Nomifensine may possess antidepressant properties beneficial for patients with Parkinson's disease experiencing depressive symptoms.